title: Intranasal sumatriptan for the acute treatment of migraine in children.
abstract: Sumatriptan is a highly effective treatment for migraine in adults but its efficacy in children has not been determined. Fourteen children with migraine (6.4 to 9.8 years of age; seven girls, six with aura) participated in a randomized double-blind placebo-controlled crossover study to evaluate the efficacy of sumatriptan nasal spray. After sumatriptan, 12 of 14 (versus 6 of 14 after placebo) reported a decrease in pain intensity (p = 0.031); complete headache relief was obtained in 9 of 14 after sumatriptan versus 2 of 14 after placebo (p = 0.016). Migraine-associated symptoms were also significantly reduced by sumatriptan.
authors.affiliation: Neuropediatric Department, University Hospital for Children and Adolescents, Erlangen, Germany. Michael.Ueberall@kinder.med.uni-erlangen.de
authors.forename: M A
authors.initials: MA
authors.lastname: Ueberall
authors.forename: D
authors.initials: D
authors.lastname: Wenzel
mesh_terms: D000281:Administration, Intranasal; D002648:Child; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008881:Migraine Disorders / Q000188:drug therapy*; D018170:Sumatriptan / Q000008:administration & dosage* / Q000627:therapeutic use*
chemical_list: D018170:Sumatriptan